Mergers & Acquisitions Mergers & Acquisitions

Biogen-Reata $7.3 billion pharma merger surmounts US antitrust hurdle; no second request issued

By Ilana Kowarski
  • 12 Sep 2023 20:01
  • 12 Sep 2023 21:07
Medicine titan Biogen’s proposed $7.3 billion purchase of orphan drugmaker Reata Pharmaceuticals can proceed as planned after the 30-day mandatory US pre-merger waiting period for the deal passed yesterday.

Biogen and Reata didn't receive an official second request asking for further detail on their transaction from either the US Department of Jus

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments

Latest News